EA201370162A1 - Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты - Google Patents

Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты

Info

Publication number
EA201370162A1
EA201370162A1 EA201370162A EA201370162A EA201370162A1 EA 201370162 A1 EA201370162 A1 EA 201370162A1 EA 201370162 A EA201370162 A EA 201370162A EA 201370162 A EA201370162 A EA 201370162A EA 201370162 A1 EA201370162 A1 EA 201370162A1
Authority
EA
Eurasian Patent Office
Prior art keywords
side effect
pharmaceutical composition
preparations
turbine
including anti
Prior art date
Application number
EA201370162A
Other languages
English (en)
Other versions
EA026922B1 (ru
Inventor
Оливер Яопу Ху
Тонхо Юн
Чэнхуэй Хсион
Вэньлян Чан
Тунюань Ших
Хсинтен Хо
Original Assignee
Нэшнл Дифенс Эдьюкейшн Энд Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нэшнл Дифенс Эдьюкейшн Энд Рисерч Фаундейшн filed Critical Нэшнл Дифенс Эдьюкейшн Энд Рисерч Фаундейшн
Publication of EA201370162A1 publication Critical patent/EA201370162A1/ru
Publication of EA026922B1 publication Critical patent/EA026922B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение предусматривает создание фармацевтической композиции для лечения туберкулезных заболеваний, не вызывающей побочный эффект/вызывающей слабый побочный эффект, содержащей фармацевтически эффективное количество одного или нескольких соединений, выбранных из группы, включающей изониазид, рифампин, пиразинамид и этамбутол и фармацевтически эффективное количество веществ, обеспечивающих снижение побочного эффекта противотуберкулезных препаратов.
EA201370162A 2011-04-20 2011-04-20 Противотуберкулезная фармацевтическая комбинация с низким побочным эффектом, включающая противотуберкулезные препараты EA026922B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/000688 WO2012142724A1 (zh) 2011-04-20 2011-04-20 无/低副作用的抗结核病药物复方

Publications (2)

Publication Number Publication Date
EA201370162A1 true EA201370162A1 (ru) 2014-04-30
EA026922B1 EA026922B1 (ru) 2017-05-31

Family

ID=47041008

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201370162A EA026922B1 (ru) 2011-04-20 2011-04-20 Противотуберкулезная фармацевтическая комбинация с низким побочным эффектом, включающая противотуберкулезные препараты

Country Status (6)

Country Link
US (1) US8969312B2 (ru)
CN (2) CN108465110A (ru)
DE (1) DE112011105169B4 (ru)
EA (1) EA026922B1 (ru)
WO (1) WO2012142724A1 (ru)
ZA (1) ZA201306395B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014170820A2 (en) * 2013-04-15 2014-10-23 Kar Santosh K A pharmaceutical combination for treating tuberculosis
TWI552748B (zh) * 2013-10-25 2016-10-11 The use of a compound for the removal of hepatotoxicity against Acetaminophen (APAP)
TWI666013B (zh) * 2013-10-25 2019-07-21 財團法人國際教育基金會 一種化合物用於去除乙醯胺基酚(Acetaminophen，APAP)藥物肝毒性之用途
EP4173619A3 (en) * 2013-11-13 2023-07-19 National Defense Education and Research Foundation New acetaminophen compound composition without side effect to liver
MY190647A (en) * 2015-09-24 2022-04-30 Sinew Pharma Inc Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
CN116440143A (zh) * 2015-11-19 2023-07-18 欣耀生医股份有限公司 预防或治疗脂肪肝的药物组合物
KR101761155B1 (ko) 2016-06-03 2017-07-25 건국대학교 산학협력단 이소람네틴 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학적 조성물
KR101833011B1 (ko) 2016-12-13 2018-02-27 건국대학교 산학협력단 람네틴 및 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 결핵 예방 또는 치료용 조성물
SG11202102697XA (en) * 2018-10-19 2021-04-29 Avalon Hepapoc Ltd Galactose oral composition and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279913C (zh) * 2002-09-10 2006-10-18 信谊药厂 一种含有利福平异烟肼的复方制剂及其制备方法
CN1857280A (zh) * 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种复方抗结核药物缓释制剂
WO2010009572A1 (zh) * 2008-07-23 2010-01-28 国防教育研究基金会 含异烟碱酰胺（isoniazid, inh）低副作用的新复方

Also Published As

Publication number Publication date
CN103391781A (zh) 2013-11-13
US8969312B2 (en) 2015-03-03
ZA201306395B (en) 2014-04-30
DE112011105169B4 (de) 2021-11-04
DE112011105169T5 (de) 2014-03-20
WO2012142724A1 (zh) 2012-10-26
EA026922B1 (ru) 2017-05-31
CN108465110A (zh) 2018-08-31
US20140038921A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
EA201370162A1 (ru) Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты
CY1123460T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
TW201613887A (en) Antiproliferative compounds and methods of use thereof
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
MX2021007651A (es) Inhibidores de ezh2 para tratar linfomas.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
IN2015DN00376A (ru)
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA202090683A2 (ru) Способы и композиции для лечения рака
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
EA201590193A1 (ru) Препараты лаквинимода без подщелачивающего агента
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
EA201690673A1 (ru) Комбинированная терапия лахинимодом для лечения рассеянного склероза
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EA201990671A1 (ru) Ингибиторы мутантных изоцитратдегидрогеназ и включающие их композиции и способы